TW202404602A - 移植後肺部病症的治療方法 - Google Patents

移植後肺部病症的治療方法 Download PDF

Info

Publication number
TW202404602A
TW202404602A TW112114416A TW112114416A TW202404602A TW 202404602 A TW202404602 A TW 202404602A TW 112114416 A TW112114416 A TW 112114416A TW 112114416 A TW112114416 A TW 112114416A TW 202404602 A TW202404602 A TW 202404602A
Authority
TW
Taiwan
Prior art keywords
participants
subject
day
berusudil
cycle
Prior art date
Application number
TW112114416A
Other languages
English (en)
Chinese (zh)
Inventor
科里 卡特勒
撒迦利亞 德飛利浦
惠淑 金
Original Assignee
美商凱德蒙有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商凱德蒙有限責任公司 filed Critical 美商凱德蒙有限責任公司
Publication of TW202404602A publication Critical patent/TW202404602A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112114416A 2022-04-19 2023-04-18 移植後肺部病症的治療方法 TW202404602A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263332628P 2022-04-19 2022-04-19
US63/332,628 2022-04-19
US202263389444P 2022-07-15 2022-07-15
US63/389,444 2022-07-15

Publications (1)

Publication Number Publication Date
TW202404602A true TW202404602A (zh) 2024-02-01

Family

ID=86330932

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112114416A TW202404602A (zh) 2022-04-19 2023-04-18 移植後肺部病症的治療方法

Country Status (11)

Country Link
US (1) US20250255867A1 (https=)
EP (1) EP4511036A1 (https=)
JP (1) JP2025513240A (https=)
KR (1) KR20250003657A (https=)
CN (1) CN119031914A (https=)
AU (1) AU2023256541A1 (https=)
CA (1) CA3249201A1 (https=)
IL (1) IL316410A (https=)
MX (1) MX2024012802A (https=)
TW (1) TW202404602A (https=)
WO (1) WO2023205153A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325938A (en) * 2023-07-17 2026-03-01 Kadmon Corp Llc Combination therapy including BTK inhibitor and BELUMOSUDIL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
CN113620933A (zh) 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
US11311541B2 (en) * 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD

Also Published As

Publication number Publication date
WO2023205153A1 (en) 2023-10-26
JP2025513240A (ja) 2025-04-24
US20250255867A1 (en) 2025-08-14
CN119031914A (zh) 2024-11-26
AU2023256541A1 (en) 2024-12-05
CA3249201A1 (en) 2023-10-26
IL316410A (en) 2024-12-01
EP4511036A1 (en) 2025-02-26
MX2024012802A (es) 2024-11-08
KR20250003657A (ko) 2025-01-07
AU2023256541A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
KR102495432B1 (ko) 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
CN115605201A (zh) 血管紧张素ii 2型受体激动剂的新用途
CN117695284A (zh) 冠状病毒感染的治疗
US11324750B2 (en) Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
RU2722641C2 (ru) Ценикривирок для лечения заболеваний печени и перитонита
Zhao et al. A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or-dependent chronic GVHD
KR20250088633A (ko) (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여하여 면역 혈소판 감소증을 치료하는 방법
TW202404602A (zh) 移植後肺部病症的治療方法
KR20230004618A (ko) 전신성 과염증 반응을 수반하는 병태 치료에 사용하기 위한 에클리타세르팁
US11160814B1 (en) Methods of treatment for disease from coronavirus exposure
Huang et al. Disseminated Fusarium solani infection in a child with acute lymphocytic leukemia: a case report and literature review
US20230381179A1 (en) Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
EP3376869B1 (en) Treatment of autoimmune disease
O’Connell et al. Idiopathic pulmonary fibrosis: treatment update
TW202133851A (zh) 治療肺動脈高血壓之方法
RAPOR Acute eosinophilic pneumonia secondary to heroin inhalation
CN113332439A (zh) 包含双重PI3Kδ-γ激酶抑制剂和皮质类固醇的治疗方法及组合物
Shastri et al. Mucormycosis, diabetes and COVID-19 pneumonia: unleashing the facts
EP4419110A1 (en) Treatment of viruses with antiviral nucleosides
TW202245799A (zh) 治療冠狀病毒感染及由其導致之發炎所誘發的肺損傷之方法
He et al. Voriconazole successfully treats intracranial Trichosporon asahii infection in an immunocompetent patient: a rare case report and literature review
US20250352520A1 (en) Use of dexpramipexole for the treatment of eosinophilic copd
TW202535375A (zh) 苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途
Karwa et al. Mucormycosis: A lethal disease